Strategic Moves and Financial Challenges

This article first appeared on GuruFocus.

• Net Loss: $30.9 million or $0.47 per share for Q3 2025.

• Adjusted Net Loss: $22.1 million or $0.34 per share, excluding non-cash charges.

• Non-Cash Charges: $8.8 million related to mark-to-market adjustment of embedded derivatives.

• Cash Burn: $22 million for the quarter.

• Cash and Investments: $36.1 million as of September 30, 2025.

• Registered Direct Offering: $20.3 million in net proceeds.

• ATM Program Proceeds: $9 million during the quarter.

• Upcoming Novo Nordisk Transaction: $240 million in upfront cash expected in Q4 2025.

• Debt Repayment Plans: $67.1 million secured term loan and $17.1 million of 2026 convertible notes to be repaid.

• Operating Expenses: $26.4 million for Q3 2025, a decrease of $6 million from Q2 2025.

• Interest Expense: Net credit of $13.4 million due to non-cash remeasurement adjustment.

• Interest and Other Income: $616,000 for Q3 2025.

• Loss from Discontinued Operations: $9.7 million, a decrease of $10.1 million from Q2 2025.

Release Date: November 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

• Omeros Corp (NASDAQ:OMER) secured a significant deal with Novo Nordisk valued at up to $2.1 billion, providing substantial upfront and milestone payments.

• The company anticipates receiving $240 million in upfront cash from the Novo Nordisk deal, which will be used to repay existing debt and fund operations.

• Omeros Corp (NASDAQ:OMER) is preparing for the commercial launch of Yartemlia, a treatment for transplant-associated thrombotic microangiopathy (TATMA), with a potential FDA approval expected by December 2025.

• The company has established a national ICD-10 diagnostic code and CPT procedural code for Yartemlia, positioning it as the only reimbursable TATMA treatment upon approval.

• Omeros Corp (NASDAQ:OMER) is advancing a diversified pipeline, including MASP2, Oncology, TCAT, and PDE7 programs, targeting major unmet medical needs.

• Omeros Corp (NASDAQ:OMER) reported a net loss of $30.9 million for the third quarter of 2025, an increase from the previous quarter.

• The company’s cash burn for the quarter was $22 million, leaving $36.1 million in cash and investments as of September 30, 2025.

• There are risks and uncertainties associated with the forward-looking statements and regulatory approvals, which could impact the company’s future performance.

• The company faces potential volatility in financial results due to non-cash mark-to-market adjustments on embedded derivatives tied to its debt.

• Omeros Corp (NASDAQ:OMER) expects operating expenses to increase in the fourth quarter of 2025, primarily due to marketing costs associated with the anticipated launch of Yartemlia.

Q: Post-approval, how quickly do you plan to launch Narsoplimab, and what are the steps involved in selling to transplant centers? A: Gregory Demopulos, CEO: Launch preparations are well underway, and we plan to move quickly post-approval. We don’t disclose revenue projections but expect to be cash flow positive by 2027. Nadia Dac, Chief Commercial Officer, added that they have identified “ready-to-go” accounts where formulary approvals are not critical for ordering and administering the drug.

Q: Can you provide details on the NTAP (New Technology Add-on Payment) for Yartemlia? A: Gregory Demopulos, CEO: NTAP assists with hospital payments and we expect to receive it for Yartemlia. Nadia Dac, Chief Commercial Officer, mentioned they submitted on time and expect a decision in 2026, which will help hospitals defray drug costs.

Q: Have there been any labeling discussions with the FDA, and why does the historical control database only include data up to 2016? A: Gregory Demopulos, CEO: We don’t comment on FDA discussions. The Kyoto data overlap with our trial data, and the timeframe is due to the publication initiation. Catherine Melfi, Chief Regulatory Officer, added that the database was rigorously collected and restarting it would take years.

Q: Has there been any recent FDA commentary on your data package and the use of historical controls? Also, what is the outlook for operating expenses in 2026? A: Gregory Demopulos, CEO: Information requests from the FDA are part of the review process. The issues with other products using historical controls are different from ours. Operating expenses are expected to increase, contingent on the deal closing and FDA approval.

Q: What are the next steps for Omeros following the Novo Nordisk transaction and potential approval of Yartemlia? A: Gregory Demopulos, CEO: We aim to secure Yartemlia approval, execute a successful launch, and advance our pipeline, including OMS 1029, MASP2 small molecules, PDE7 program, TCAT platform, and oncology franchise. The Novo Nordisk transaction provides capital and validates our science.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.